Occult hepatitis B virus infection in a North American adult Hemodialysis patient population

被引:112
作者
Minuk, GY
Sun, DF
Greenberg, R
Zhang, M
Hawkins, K
Uhanova, J
Gutkin, A
Bernstein, K
Giulivi, A
Osiowy, C
机构
[1] Univ Manitoba, Dept Med, John Buhler Res Ctr, Sect Hepatol,Liver Dis Unit, Winnipeg, MB R3E 3P4, Canada
[2] Univ Manitoba, Dept Med, Nephrol Sect, Winnipeg, MB R3E 3P4, Canada
[3] Canadian Sci Ctr Human & Anim Hlth, Winnipeg, MB, Canada
[4] Hlth Canada, Ottawa, ON K1A 0L2, Canada
关键词
D O I
10.1002/hep.20435
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis B virus (HBV) infections continue to occur in adult hemodialysis units. A possible contributing factor is the presence of occult HBV (serum hepatitis B surface antigen [HBsAg] negative but HBV DNA positive). Two hundred forty-one adult hemodialysis patients were screened for occult HBV. HBV DNA testing was performed by real-time polymerase chain reaction (PCR) with 2 independent primer sets (core promoter and surface). Two (0.8%) of the 241 patients were HBsAg positive. Of the remaining 239 HBsAg-negative patients, 9 (3.8%) were HBV DNA positive. Viral loads in these individuals were low (10(2)-10(4) viral copies/mL). Seven of the 9 (78%) were nt 587 mutation (sG145R mutant) positive. Demographic, biochemical, and HBV serological testing did not help to identify those with occult HBV. In conclusion, the prevalence of occult HBV in adult hemodialysis patients in this North American urban center is approximately 4 to 5 times higher than standard HBsAg testing would suggest. The majority of these infections are associated with low viral loads and a high prevalence of the sG145R mutant. Finally, the demographic, biochemical, and/or serological features of HBV DNA-positive subjects do not distinguish these individuals from the remainder of the dialysis patient population.
引用
收藏
页码:1072 / 1077
页数:6
相关论文
共 35 条
[1]   COST-BENEFIT OF VACCINATION FOR HEPATITIS-B IN HEMODIALYSIS CENTERS [J].
ALTER, MJ ;
FAVERO, MS ;
FRANCIS, DP .
JOURNAL OF INFECTIOUS DISEASES, 1983, 148 (04) :770-771
[2]  
Ambühl PM, 2000, SCHWEIZ MED WSCHR, V130, P341
[3]   TRANSMISSION OF SEROLOGICALLY SILENT HEPATITIS-B VIRUS ALONG WITH HEPATITIS-C VIRUS IN 2 CASES OF POSTTRANSFUSION HEPATITIS [J].
BAGINSKI, I ;
CHEMIN, I ;
HANTZ, O ;
PICHOUD, C ;
JULLIEN, AM ;
CHEVRE, JC ;
LI, JS ;
VITVITSKI, L ;
SNINSKY, JJ ;
TREPO, C .
TRANSFUSION, 1992, 32 (03) :215-220
[4]   Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen:: Clinically significant or purely "occult"? [J].
Bréchot, C ;
Thiers, V ;
Kremsdorf, D ;
Nalpas, B ;
Pol, S ;
Paterlini-Bréchot, P .
HEPATOLOGY, 2001, 34 (01) :194-203
[5]  
Cabrerizo M, 1997, J AM SOC NEPHROL, V8, P1443
[6]   VACCINE-INDUCED ESCAPE MUTANT OF HEPATITIS-B VIRUS [J].
CARMAN, WF ;
ZANETTI, AR ;
KARAYIANNIS, P ;
WATERS, J ;
MANZILLO, G ;
TANZI, E ;
ZUCKERMAN, AJ ;
THOMAS, HC .
LANCET, 1990, 336 (8711) :325-329
[7]  
*CDC, 1977, 41 CDC, P12
[8]  
Centers for Disease Control, 1988, MMWR Morb Mortal Wkly Rep, V37, P377
[9]   OCCULT HEPATITIS-B VIRUS AS SOURCE OF INFECTION IN LIVER-TRANSPLANT RECIPIENTS [J].
CHAZOUILLERES, O ;
MAMISH, D ;
KIM, M ;
CAREY, K ;
FERRELL, L ;
ROBERTS, JP ;
ASCHER, NL ;
WRIGHT, TL .
LANCET, 1994, 343 (8890) :142-146
[10]   OBSERVATIONS ON DECREASED SERUM GLUTAMIC OXALACETIC TRANSAMINASE (SGOT) ACTIVITY IN AZOTEMIC PATIENTS [J].
COHEN, GA ;
GOFFINET, JA ;
DONABEDIAN, RK ;
CONN, HO .
ANNALS OF INTERNAL MEDICINE, 1976, 84 (03) :275-280